ALBERT DAVID LIMITED, a major Pharmaceutical Company has made a decisive foray into the area of Research & Development by signing a MOU (Memorandum of Understanding) with the premier and prestigious Calcutta University. Such tie-up’s between Pharmaceutical Companies and Research oriented Universities will not only strengthen the future prospects of Indian Pharmaceutical Companies in the post GATT era but also encourage and provide financial support to brains of India to excel as well.

ALBERT DAVID, a part of the well-known Calcutta based Industrial House of Kotharis is accredited with various distinguished technical with the likes of Rousell Morishto of Japan, which is a subsidiary of Ajinomoto Co. Inc., the world’s largest manufacturer of amino acids. Along with M/s Phrmaplan GmBH of Germany, ALBERT DAVID had also successfully established a landmark in marketing of the prostaglandin of UPJOHN USA.

ALBERT DAVID LIMITED made a modest start in 1924 with a single manufacturing facility. Today, its manufacturing capabilities extend to three manufacturing units located in Calcutta, Ghaziabad and Mandideep. The Ghaziabad & Mandideep WHO CMP & ISO 9002 certified and the Calcutta bulk drug is USA FDA approved. ALBERT DAVID is further strengthening its manufacturing capabilities by setting up yet another state-of-the-art facility in Calcutta which will be second to none and will comply will all International Standards.

ALBERT DAVID’s core competence stands out in the manufacturing of pecialty Formulations, Herbal Products, Disposable Syringes & Needles, Bulk Drugs and I.V Solutions. This Company also pioneered the use of EFS Technology in I.V Fluids in India.

ALBERT DAVID LIMITED has a strong presence in various drug therapeutic classes like Immunomodulators, Vitamins & Nutritional Supplements, NSAIDs, Apetite Stimulants, Liver Protectives, Anti-Ulcerants, Laxatives, Anti-Arthiritic Preparations, Muscle Relaxants, and Adaptogenics to name a few. They have concrete plans to further diversify into lifestyle segments like Cardiovascular Therapy, Anti-Diabetic drugs and Psychotropic agents.

Recognizing the need of the post GATT era will be effective from January 2005 and in continuance of the recognition of the academia ALBERT DAVID proudly pioneers the joint collaboration work with the illustrious University of Calcutta in the field of Research & Development. The strategic response to the future needs and timely investment in this regard will enable and gear up ALBERT DAVID LIMITED to prepare itself and successfully meet the post GATT era challenges.

The direct interaction and such collaboration between Business conglomerates and academics certainly helps to discover new molecules & products for the benefits of the masses, such strong bondages will be definitely mutually beneficial.

Though this is the humble beginning, we are looking forward to much bigger involvements, both financial and academic.

Testing of RM, PM, BULK,
WFI, Inprocess & Finished

products by:

Chemical Analysis
Instrumental Analysis – includes Spectro Photometry, Polarimetry, Chromatography (TLC, HPLC etc)
Physical Analysis
Microbiological Analysis
Pharmacological Analysis
Biochemical Analysis
Our quality objectives are:
To provide the safest formulation in different dosage forms in the market.
To keep the equipment, the process and the products updated with technological advance corresponding to international quality standards.
To satisfy our customers within India and abroad with timely delivery and "zero defect" product.
To ensure cost effective systems in our operations and to achieve quality and productivity.
To enhance productivity through improved working methods and motivated employees.
To encourage employee’s involvement at par with the management and to achieve congenial and healthy working atmosphere.
To provide efficient service to the customers.
Development for new formulations is carried out by R&D Team.
Quality Assurance :

Monitoring of quality standard / good manufacturing practices at each and every stage of manufacturing.

We strictly follow the following factors to achieve quality products:

Selection and control of drug component – RM/PM
For parenteral products quality – special processing of water system is required including dimineralization / multi column distillation to get high quality WFI.
Manufacturing environment control - giving special classroom facilities to control air borne particulate matter and micro-organizms.
Proper selection of filtration system - to control liquid borne particulate matter.
Selection & control of sterilization methods to control viable micro-organisms.
Selection of proper labelling and packaging to meet drug regulation / market acceptance.
Self Inspection & Auditing:

Periodically a separate area is audited by the internal audit team with persons responsible for that area. The audit covers the personnel, premises, equipment, procedures and documentation. The findings of the inspection are discussed with the concerned person and the report alongwith recommendations is submitted to the in-charge of the concerned department for necessary action. The result of the periodic and annual inspection is maintained by the quality assurance department.

We have achieved:
GMP certificate from Iran.
GMP certificate from Budapest, Hungary.
GMP certificate from Directorate of Drugs Control, Govt. of West Bengal.
Approval from FDA, USA.

Top
.